This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.
Marco Antonio Stephano
Advertisement
Marco Antonio Stephano is professor at the University of Sao Paulo, Sao Paulo, Brazil.
Articles by Marco Antonio Stephano
Advertisement
Latest Updated Articles
Brazilian Regulation of Biosimilar Products: What Is Important to KnowPublished: September 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
2
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
3
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
4
Establishing Risk Assessments for AI in Bio-Manufacturing
5
